Exodus Movement Gets Approval to Uplist to NYSE American-May 2024-www.financetom.com

Publish for free

financetom

Business

/

Business

/

Exodus Movement Gets Approval to Uplist to NYSE American

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Exodus Movement Gets Approval to Uplist to NYSE American

Dec 13, 2024 7:39 AM

10:14 AM EST, 12/13/2024 (MT Newswires) -- Exodus Movement ( EXOD ) said Friday that its class A common shares have been approved for listing at the NYSE American Stock Exchange.

The company said its securities will be uplisted to the NYSE American Stock Exchange on Wednesday, with its shares traded under the ticker symbol, "EXOD."

Price: 33.00, Change: -0.25, Percent Change: -0.75

Previous page： DexCom Likely to Sustain Stability in 2025, Morgan Stanley Says Next page： --Louisiana-Pacific Lifts Quarterly Dividend 8% to $0.28 a Share, Payable March 13 to Holders on Feb. 27

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Sign up to post

Show More Comments

Related Articles >

DexCom Likely to Sustain Stability in 2025, Morgan Stanley Says

DexCom Likely to Sustain Stability in 2025, Morgan Stanley Says

12:08 PM EST, 02/14/2025 (MT Newswires) -- DexCom's ( DXCM ) Q4 results demonstrated the company's stable performance, with expectations for it to continue, Morgan Stanley said in a Friday note. After a rockier couple quarters, the print was encouraging in as much as it demonstrated stability, and we came away with expectations for more of the same with a...

--Louisiana-Pacific Lifts Quarterly Dividend 8% to $0.28 a Share, Payable March 13 to Holders on Feb. 27

--Louisiana-Pacific Lifts Quarterly Dividend 8% to $0.28 a Share, Payable March 13 to Holders on Feb. 27

12:14 PM EST, 02/14/2025 (MT Newswires) -- Price: 111.69, Change: -0.58, Percent Change: -0.52 ...

BRIEF-Diamondback In Talks To Buy Permian Producer Double Eagle - WSJ

BRIEF-Diamondback In Talks To Buy Permian Producer Double Eagle - WSJ

Feb 14 (Reuters) - * DIAMONDBACK IN TALKS TO BUY PERMIAN PRODUCER DOUBLE EAGLE - WSJ * DEAL COULD VALUE DOUBLE EAGLE AT MORE THAN $5 BILLION IS EXPECTED IN COMING DAYS- WSJ Source text: https://tinyurl.com/2bspkm3f ...

AstraZeneca's Bladder Cancer Treatment Improves Survival in Phase 3 Trial

AstraZeneca's Bladder Cancer Treatment Improves Survival in Phase 3 Trial

12:06 PM EST, 02/14/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Friday that results from its phase 3 trial showed its bladder cancer treatment candidate, Imfinzi, improved event-free survival and overall survival in patients with muscle-invasive bladder cancer. The benefits were observed regardless of whether patients achieved a pathologic complete response, according to the company. Patients in the study...

About

Terms and Conditions Privacy policy Cookie Settings Contact Us

Services

financetom Market Personal Finance Business Economy Cryptocurrency MAP

Copyright 2023-2025 - www.financetom.com All Rights Reserved